Strong funding Rejuvenate Bio has raised a total of $40M in funding and reports annual revenue in the range of $10M-$25M, indicating a solid financial base to collaborate on large-scale gene expression and epigenetic reprogramming programs.

Strategic partnerships Recent high-profile partnerships with Merck Group and Merck Animal Health USA suggest open channels for co-development, regulatory expertise, and potential access to capital and manufacturing capabilities for translational therapies.

Harvard lineage Founded on scientific research from the Wyss Institute at Harvard Medical School, signaling strong credibility in innovative gene expression approaches that may align with customers seeking cutting-edge longevity and organ-disease interventions.

Clinical focus Targeting core drivers of chronic age-related diseases across humans and animals, with potential cross-species opportunities for partnerships, diagnostics, and companion animal programs alongside human therapeutics.

Recognition and visibility Industry recognition through live-pitch awards and speaking engagements at TechCon SoCal and related events elevates profile, creating doors for introductions to institutional buyers and potential channel partners.